CD8 + CTLs are the most common cytotoxic effector cell in circulation, and knowledge of how to improve CD8 + CTL efficacy in AML with potential partners such as BH3 mimetics remains an area of clinical importance. Here, CD8A is linked to acute myeloid leukemia.